TrialPanorama/TrialPanorama-database huggingface dataset:
Primary endpoint: Change in Coronary Artery Flow
Endpoint domain: Physiological/clinical
Endpoint subdomain: Cardiovascular outcomes
Primary endpoint: Improvement in knee function
Endpoint domain: Physiological/clinical
Endpoint subdomain: Musculoskeletal and connective tissue outcomes
Primary endpoint: Deviation >5 mmHg in MAP
Endpoint domain: Physiological/clinical
Endpoint subdomain: Cardiovascular outcomes
Primary endpoint: Change in Lung function
Endpoint domain: Physiological/clinical
Endpoint subdomain: Respiratory outcomes
Primary endpoint: Safety assessed by development of RLT and AEs
Endpoint domain: Adverse events/effects
Primary endpoint: Comparison of serum concentrations (Cmax/Steady State)
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Center of pressure displacement
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: HIV Viral Load Change
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Number of Patients With Ocular or Systemic Dose Limiting Events
Endpoint domain: Adverse events/effects
Primary endpoint: Change in renal endothelial function
Endpoint domain: Physiological/clinical
Endpoint subdomain: Renal and urinary outcomes
Primary endpoint: Objective response or tumoral stability by RECIST criteria
Endpoint domain: Physiological/clinical
Endpoint subdomain: Neoplasms and related outcomes
Primary endpoint: Deterioration in the Spitzer QoL Index score of ≥ 2 points
Endpoint domain: Life impact
Endpoint subdomain: Global quality of life
Primary endpoint: No grade 4 arterial hypertension, grade 3-4 thromboembolic event, grade 3-4 cardiac insufficiency, and hospitalization not related to chemotherapy
Endpoint domain: Adverse events/effects
Primary endpoint: Change in gastric volume
Endpoint domain: Physiological/clinical
Endpoint subdomain: Gastrointestinal outcomes
Primary endpoint: Clinician-Reported Submental Fat Rating Scale (CR-SMFRS) 1-grade Response
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Subject Self Rating Scale (SSRS) Response
Endpoint domain: Life impact
Endpoint subdomain: Perceived health status
Primary endpoint: Percentage of Participants With Systemic Events Within 7 Days After Each Vaccination
Endpoint domain: Adverse events/effects
Primary endpoint: Percentage of Participants With Adverse Events (AEs) Within 1 Month After Each Vaccination
Endpoint domain: Adverse events/effects
Primary endpoint: Percentage of Participants With Serious Adverse Events (SAEs) From the First Vaccination up to 6 Months After Last Vaccination
Endpoint domain: Adverse events/effects
Primary endpoint: Percentage of Participants With Newly Diagnosed Chronic Medical Condition (NDCMC) up to 6 Months After Last Vaccination
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Positive programmed ventricular stimulation
Endpoint domain: Physiological/clinical
Endpoint subdomain: Cardiovascular outcomes
Primary endpoint: Radiological tumor response before surgery
Endpoint domain: Physiological/clinical
Endpoint subdomain: Neoplasms and related outcomes
Primary endpoint: Pathologic response rate and histological degree of tumor regression
Endpoint domain: Physiological/clinical
Endpoint subdomain: Neoplasms and related outcomes
Primary endpoint: Time to first day of drinking
Endpoint domain: Life impact
Endpoint subdomain: Perceived health status
Primary endpoint: Time to first day of heavy drinking
Endpoint domain: Life impact
Endpoint subdomain: Perceived health status
Primary endpoint: Killing of conjunctival bacterial flora
Endpoint domain: Physiological/clinical
Endpoint subdomain: Infections and infestations outcomes
Primary endpoint: Change of Well-Being
Endpoint domain: Life impact
Endpoint subdomain: Global quality of life
Primary endpoint: Reduction in Mean Alkaline Phosphatase (ALP)
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Normalization of ALP below the upper limit of normal
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: accuracy
Endpoint domain: Physiological/clinical
Endpoint subdomain: Cardiovascular outcomes
Primary endpoint: Visual Analogue Scale (VAS) Scores
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Modified Bleeding Index (mBI)
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Percent of Participants Experiencing Cardiac Events
Endpoint domain: Physiological/clinical
Endpoint subdomain: Cardiovascular outcomes
Primary endpoint: Success of repeated percutaneous coronary intervention
Endpoint domain: Physiological/clinical
Endpoint subdomain: Cardiovascular outcomes
Primary endpoint: Change from baseline in parent-child relationship
Endpoint domain: Life impact
Endpoint subdomain: Emotional functioning/wellbeing
Primary endpoint: Change from baseline in responsive caregiving practices
Endpoint domain: Life impact
Endpoint subdomain: Delivery of care
Primary endpoint: Change from baseline in child development
Endpoint domain: Life impact
Endpoint subdomain: Physical functioning
Primary endpoint: Complete response at 24 hr
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Number of evaluations after 4 weeks treatment
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Early Allograft Dysfunction (EAD)
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Mask usability
Endpoint domain: Life impact
Endpoint subdomain: Perceived health status
Primary endpoint: Mask performance
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Mean Adherence to the Supplement Regimen
Endpoint domain: Life impact
Endpoint subdomain: Perceived health status
Primary endpoint: Response to locally injected drugs
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Fractional excretion of phosphate
Endpoint domain: Physiological/clinical
Endpoint subdomain: Metabolic and nutritional outcomes
Primary endpoint: bioavailability of Modified Release formulations
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Frequency of TRL7 c.32A>T SNP carriers
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: tumor oxygenation
Endpoint domain: Physiological/clinical
Endpoint subdomain: Neoplasms and related outcomes
Primary endpoint: Median Cumulative Therapeutic Warfarin Dose (Milligrams)
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Change from Baseline of Diastolic Blood Pressure in mmHg
Endpoint domain: Physiological/clinical
Endpoint subdomain: Cardiovascular outcomes
Primary endpoint: Change from Baseline of Systolic Blood Pressure in mmHg
Endpoint domain: Physiological/clinical
Endpoint subdomain: Cardiovascular outcomes
Primary endpoint: Change from Baseline in Heart Rate in beats per minute
Endpoint domain: Physiological/clinical
Endpoint subdomain: Cardiovascular outcomes
Primary endpoint: Area under the NN1250 concentration-time curve after single dose
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Degree of colonisation of the central venous catheter
Endpoint domain: Physiological/clinical
Endpoint subdomain: Infections and infestations outcomes
Primary endpoint: Safety of GX-I7 compared to placebo
Endpoint domain: Adverse events/effects
Primary endpoint: Reduction of adverse drug events (ADE)
Endpoint domain: Adverse events/effects
Primary endpoint: Cmax of probe substrates
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Tmax of probe substrates
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: AUClast of probe substrates
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: AUCinf of probe substrates
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: t1/2 of probe substrates
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Cl of intravenous midazolam
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Successful Imaging of the Mucosa
Endpoint domain: Physiological/clinical
Endpoint subdomain: Gastrointestinal outcomes
Primary endpoint: Change in parent child communication
Endpoint domain: Life impact
Endpoint subdomain: Communication
Primary endpoint: Change in intentions for sex
Endpoint domain: Life impact
Endpoint subdomain: Perceived health status
Primary endpoint: Correlation between EEG alpha band degree and frequency
Endpoint domain: Physiological/clinical
Endpoint subdomain: Nervous system outcomes
Primary endpoint: Change in correlation of EEG alpha band degree and frequency
Endpoint domain: Physiological/clinical
Endpoint subdomain: Nervous system outcomes
Primary endpoint: Response to Food Related Cues in Superior Frontal Region
Endpoint domain: Physiological/clinical
Endpoint subdomain: Nervous system outcomes
Primary endpoint: Response to Food Related Cues in Anterior Cingulate Region
Endpoint domain: Physiological/clinical
Endpoint subdomain: Nervous system outcomes
Primary endpoint: Response to Food Related Cues in Hippocampal Region 1
Endpoint domain: Physiological/clinical
Endpoint subdomain: Nervous system outcomes
Primary endpoint: Response to Food Related Cues in Hippocampal Region 2
Endpoint domain: Physiological/clinical
Endpoint subdomain: Nervous system outcomes
Primary endpoint: Response to Food Related Cues in Superior Parietal Region
Endpoint domain: Physiological/clinical
Endpoint subdomain: Nervous system outcomes
Primary endpoint: Sensitivity and Specificity of PET/CT Imaging
Endpoint domain: Physiological/clinical
Endpoint subdomain: Renal and urinary outcomes
Primary endpoint: Number of Participants With Near Term Relapse
Endpoint domain: Adverse events/effects
Primary endpoint: Effectiveness of ACAP Confirm ® algorithm in management of atrial capture
Endpoint domain: Physiological/clinical
Endpoint subdomain: Cardiovascular outcomes
Primary endpoint: incidence of complete ulcer closure
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Loss of cold sensation
Endpoint domain: Physiological/clinical
Endpoint subdomain: Nervous system outcomes
Primary endpoint: timespan until sufficient use of noninvasive ventilation
Endpoint domain: Physiological/clinical
Endpoint subdomain: Respiratory outcomes
Primary endpoint: Change in total score
Endpoint domain: Life impact
Endpoint subdomain: Global quality of life
Primary endpoint: Change From Baseline in Single-handed Nail Psoriasis Severity Index (shNAPSI)
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Plasma NGAL levels
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Percentage of Participants With Serological Response to Vaccination (VNA Titers)
Endpoint domain: Physiological/clinical
Endpoint subdomain: Immune system outcomes
Primary endpoint: Percentage of Participants With Serological Response to Vaccination (S-ELISA)
Endpoint domain: Physiological/clinical
Endpoint subdomain: Immune system outcomes
Primary endpoint: Antibody Geometric Mean Titers (GMTs)
Endpoint domain: Physiological/clinical
Endpoint subdomain: Immune system outcomes
Primary endpoint: Number of eye drops and gel instilled
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Number of patients with hyperinsulinemia
Endpoint domain: Physiological/clinical
Endpoint subdomain: Metabolic and nutritional outcomes
Primary endpoint: Number of patients with hyperlipidemia
Endpoint domain: Physiological/clinical
Endpoint subdomain: Metabolic and nutritional outcomes
Primary endpoint: Number of patients with albuminuria
Endpoint domain: Physiological/clinical
Endpoint subdomain: Renal and urinary outcomes
Primary endpoint: closure of the fistula
Endpoint domain: Physiological/clinical
Endpoint subdomain: Surgical and medical procedures outcomes
Primary endpoint: Aneurysm expansion rate
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Post-operative safety rates
Endpoint domain: Adverse events/effects
Primary endpoint: Atrial fibrillation symptoms
Endpoint domain: Life impact
Endpoint subdomain: Perceived health status
Primary endpoint: Change in Hepatic Venous Pressure Gradient (HVPG)
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Type, Frequency and Intensity of Adverse Events (AEs)
Endpoint domain: Adverse events/effects
Primary endpoint: Time to first identification of cardiac dysfunction
Endpoint domain: Physiological/clinical
Endpoint subdomain: Cardiovascular outcomes
Primary endpoint: Number of Participants With Non-severe Ocular Adverse Events
Endpoint domain: Adverse events/effects
Primary endpoint: Number of Participants With Severe Ocular Adverse Events
Endpoint domain: Adverse events/effects
Primary endpoint: Number of Participants With Non-severe Non-ocular Adverse Event
Endpoint domain: Adverse events/effects
Primary endpoint: Number of Participants With Severe Non-ocular Adverse Event
Endpoint domain: Adverse events/effects
Primary endpoint: Proportion of patients with any polyp or high risk polyp
Endpoint domain: Physiological/clinical
Endpoint subdomain: Neoplasms and related outcomes
Primary endpoint: Response of Intracranial Metastases
Endpoint domain: Physiological/clinical
Endpoint subdomain: Neoplasms and related outcomes
Primary endpoint: Nuclear Factor Kappa Beta concentration
Endpoint domain: Physiological/clinical
Endpoint subdomain: Immune system outcomes
Primary endpoint: Fasting Insulin concentration
Endpoint domain: Physiological/clinical
Endpoint subdomain: Metabolic and nutritional outcomes
Primary endpoint: Insulin resistance by HOMA index
Endpoint domain: Physiological/clinical
Endpoint subdomain: Metabolic and nutritional outcomes
Primary endpoint: Abnormal growth
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Delayed sexual maturation
Endpoint domain: Physiological/clinical
Endpoint subdomain: Reproductive system and breast outcomes
Primary endpoint: Abnormal bone mineral density
Endpoint domain: Physiological/clinical
Endpoint subdomain: Musculoskeletal and connective tissue outcomes
Primary endpoint: Change in skin carotenoid concentration
Endpoint domain: Physiological/clinical
Endpoint subdomain: Skin and subcutaneous tissue outcomes
Primary endpoint: Roland Morris questionnaire
Endpoint domain: Life impact
Endpoint subdomain: Physical functioning
Primary endpoint: digital algometer (Wagner, FPIX model)
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Any change in treatment
Endpoint domain: Adverse events/effects
Primary endpoint: CEUS LI-RADS Grades
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Area Under the Concentration-Time Curve From Time Zero Extrapolated to Infinity (AUCinf) of Midazolam
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Area Under the Plasma Concentration-Time Curve From Time Zero to the Time of Last Quantifiable Concentration (AUClast) of Midazolam
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Number of patients with side effects
Endpoint domain: Adverse events/effects
Primary endpoint: Change in Seizures Frequency
Endpoint domain: Physiological/clinical
Endpoint subdomain: Nervous system outcomes
Primary endpoint: Median Blink Amplitude
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Mean Change From Baseline in Disease-activity Score 28-Erythrocyte Sedimentation Rate
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Lung chronic rejection outcome
Endpoint domain: Physiological/clinical
Endpoint subdomain: Respiratory outcomes
Primary endpoint: changes in cumulative or average slow-wave activity
Endpoint domain: Physiological/clinical
Endpoint subdomain: Sleep
Primary endpoint: Percentage of index cases with at least one sexual partner treated
Endpoint domain: Resource use
Endpoint subdomain: Need for further intervention
Primary endpoint: Number of sexual partners per index case treated
Endpoint domain: Resource use
Endpoint subdomain: Other resource use
Primary endpoint: Reduction in Young Mania Rating Scale (YMRS) total score
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Hip dislocation incidence
Endpoint domain: Adverse events/effects
Primary endpoint: Oxygen saturation of the colon
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Colonic perfusion in the marginal artery
Endpoint domain: Physiological/clinical
Endpoint subdomain: Gastrointestinal outcomes
Primary endpoint: Number of Participants With Discontinuations Due to AEs
Endpoint domain: Adverse events/effects
Primary endpoint: Carboxylation of osteocalcin
Endpoint domain: Physiological/clinical
Endpoint subdomain: Metabolic and nutritional outcomes
Primary endpoint: Recurrence of hypertrophic scar
Endpoint domain: Physiological/clinical
Endpoint subdomain: Skin and subcutaneous tissue outcomes
Primary endpoint: Change in asthma-associated expenditures
Endpoint domain: Resource use
Endpoint subdomain: Other resource use
Primary endpoint: Change from baseline in Asthma Control Test (ACT)
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Diagnosis of prosthetic valve infective endocarditis
Endpoint domain: Physiological/clinical
Endpoint subdomain: Infections and infestations outcomes
Primary endpoint: Castration-resistant prostate cancer free survival
Endpoint domain: Mortality/survival
Primary endpoint: Development of patients' Distress
Endpoint domain: Life impact
Endpoint subdomain: Emotional functioning/wellbeing
Primary endpoint: Number of patients with major bleedings
Endpoint domain: Physiological/clinical
Endpoint subdomain: Infections and infestations outcomes
Primary endpoint: Number of patients with symptomatic recurrent Venous Thrombus Embolism (VTE)
Endpoint domain: Physiological/clinical
Endpoint subdomain: Cardiovascular outcomes
Primary endpoint: Change From Baseline for Average Blood Glucose
Endpoint domain: Physiological/clinical
Endpoint subdomain: Metabolic and nutritional outcomes
Primary endpoint: Prostate-Specific Antigen (PSA) Response
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Area under the flupentixol plasma concentration-time curve from zero to 72 hours post dose (AUC0-72h)
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Maximum observed concentration (Cmax) of flupentixol
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Area under the melitracen plasma concentration-time curve from zero to 72 hours post dose (AUC0-72h)
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Maximum observed concentration (Cmax) of melitracen
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Proportion of Food Allergic Participants Who Pass a DBPCFC
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Change in KOOS pain subscale
Endpoint domain: Life impact
Endpoint subdomain: Pain
Primary endpoint: Delay of degenerative beta-cells in pancreas
Endpoint domain: Physiological/clinical
Endpoint subdomain: Endocrine outcomes
Primary endpoint: ADHD-RS-IV score
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Change in cognitive function summary score
Endpoint domain: Life impact
Endpoint subdomain: Cognitive functioning
Primary endpoint: Numeric Pain Assessment Scale
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Maximum tolerated dose of CD4+CD25+ cells/kg
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Incidence of grade 3-5 infusional toxicity
Endpoint domain: Adverse events/effects
Primary endpoint: stress at work
Endpoint domain: Life impact
Endpoint subdomain: Emotional functioning/wellbeing
Primary endpoint: stress in a medical unit
Endpoint domain: Life impact
Endpoint subdomain: Emotional functioning/wellbeing
Primary endpoint: Maternal circulating concentrations of 25-hydroxyvitamin D
Endpoint domain: Physiological/clinical
Endpoint subdomain: Metabolic and nutritional outcomes
Primary endpoint: Maternal circulating concentrations of 1,25-dihydroxyvitamin D
Endpoint domain: Physiological/clinical
Endpoint subdomain: Metabolic and nutritional outcomes
Primary endpoint: Maternal circulating concentrations of 24,25-dihydroxyvitamin D
Endpoint domain: Physiological/clinical
Endpoint subdomain: Metabolic and nutritional outcomes
Primary endpoint: Population kinetics for methadone and its enantiomers
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Reflected laser radiation intensity
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Long term ophthalmological outcome
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Test-Retest Reliability of the Mindful Eating Questionnaire
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Coagulation (Anti-Xa levels)
Endpoint domain: Physiological/clinical
Endpoint subdomain: Blood and lymphatic system outcomes
Primary endpoint: Change in International Prostate Symptom Score (IPSS) total score
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Disease burden
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Duration of rotavirus shedding
Endpoint domain: Physiological/clinical
Endpoint subdomain: Infections and infestations outcomes
Primary endpoint: Rotavirus genotypes
Endpoint domain: Physiological/clinical
Endpoint subdomain: Infections and infestations outcomes
Primary endpoint: Treatment retention rate
Endpoint domain: Resource use
Endpoint subdomain: Need for further intervention
Primary endpoint: Treatment attendance rate
Endpoint domain: Resource use
Endpoint subdomain: Need for further intervention
Primary endpoint: Urinary assessment
Endpoint domain: Physiological/clinical
Endpoint subdomain: Renal and urinary outcomes
Primary endpoint: Observer-rated Dysphagia
Endpoint domain: Physiological/clinical
Endpoint subdomain: Gastrointestinal outcomes
Primary endpoint: Perception of symptoms variability
Endpoint domain: Life impact
Endpoint subdomain: Perceived health status
Primary endpoint: Impact of symptom variability on daily life activities
Endpoint domain: Life impact
Endpoint subdomain: Physical functioning
Primary endpoint: Number of Participants Diagnosed With Dry Eye Disease
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: breast cell proliferation levels
Endpoint domain: Physiological/clinical
Endpoint subdomain: Reproductive system and breast outcomes
Primary endpoint: PGE production reduction
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: AUC 0-8 h
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: GIRmax
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes